The smoking-cessation drug varenicline (Chantix, Pfizer) may increase the risk of cardiovascular adverse events, according to an updated safety review from FDA.
FDA and EMA Accepts Applications for New Nusinersen Regimen
January 23rd 2025An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower FDA-approved dosage.
Read More